Risedronate Sodium NDC 60505-3096

NDC codes

FDA NDC Directory

Product NDC (as listed)60505-3096Labeler and product segments. Claims need a package NDC.

Product NDC at billing width60505-3096Add the package segment from the table below.

Package NDCs as listed with the FDA, and the 11-digit 5-4-2 form used on claims. The highlighted digit is the added leading zero.
Package NDC	11-digit (billing)	Package	Copy
60505-3096-2	60505309602	1 BLISTER PACK in 1 CARTON (60505-3096-2) / 2 TABLET, FILM COATED in 1 BLISTER PACKMarketed from Jun 11, 2014

How the 11-digit form is made: The package segment has 1 digit, so one leading zero is added to it (5-4-1 → 5-4-2). Formatting the NDC does not by itself make it billable — the product, package and quantity must match what was dispensed or administered, and payer rules apply. Conversion rules

Product information

Brand name (proprietary): Risedronate Sodium
Generic name (nonproprietary): risedronate sodium
Active ingredients: Risedronate sodium — 75 mg/1
Dosage form: Tablet, Film coated
Route: Oral
Labeler: Apotex Corp.
Product type: Prescription drug
Marketing category: ANDA — Abbreviated New Drug Application (generic)Application ANDA 090877
Marketing start: Jun 11, 2014
Listing expires: Dec 31, 2027
Other FDA classes: Diphosphonates (Chemical structure)
Identifiers: Product ID 60505-3096_03750616-5c88-729a-215e-3d796f8ba6a8SPL ID 03750616-5c88-729a-215e-3d796f8ba6a8SPL set ID b90f2e5b-10b8-29a7-0360-31bd0dae0ec2RxCUI 905024, 905028, 905083UNII OFG5EXG60LUPC 0360505309627
Pharmacologic class: Bisphosphonate

Billing references

What Med-Code can say about coding this product, and where each statement comes from. Nothing here is inferred from the name alone.

HCPCS codeNo match

No HCPCS code in Med-Code's directory. Oral products like this are usually dispensed by a pharmacy and billed by NDC.

NDC on a medical claim

N460505309602 followed by a unit qualifier and the quantity

Package 60505-3096-02. Unit qualifiers: F2 (international unit), GR (gram), ME (milligram), ML (milliliter), UN (unit (each)). The qualifier and quantity depend on what was given. About the N4 qualifier

Product label

Current FDA label (SPL), effective Mar 2, 2026.

Indications (excerpt from the label)

Risedronate sodium tablets, USP are a bisphosphonate indicated for: Treatment and prevention of postmenopausal osteoporosis ( 1.1 ) Treatment to increase bone mass in men with osteoporosis ( 1.2 ) Treatment and prevention of glucocorticoid-induced osteoporosis ( 1.3 ) Treatment of Paget's disease ( 1.4 ) Limitations of Use Optimal duration of use has not been determined. For patients at low-risk for fracture, consider drug discontinuation after 3 to 5 years of use. ( 1.5 ) 1.1 Postmenopausal Osteoporosis Risedronate sodium tablets, USP are indicated for the treatment and prevention of osteoporosis in postmenopausal women. In postmenopausal women with osteoporosis, risedronate sodium tablets,…

Excerpt only. Read the full label for complete information.

Full label on DailyMed (opens in a new tab)

Other NDCs under ANDA 090877

Products listed under the same FDA application: other strengths and forms, and repackagers who relabel the same product.

FDA NDC Directory listings under ANDA 090877
Product	Strength	Form · route	Labeler	Product NDC
Risedronate Sodium	Risedronate sodium 150 mg/1	Tablet, Film coatedOral	Apotex Corp.	60505-3097
Risedronate Sodium	Risedronate sodium 35 mg/1	Tablet, Film coatedOral	Apotex Corp.	60505-3165
Risedronate Sodium	Risedronate sodium 35 mg/1	Tablet, Film coatedOral	Proficient Rx LP	71205-714